Relevant bibliographies by topics / Dopamine receptors

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Dopamine receptors'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dopamine receptors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dopamine receptors"

1

Jose, P. A., J. R. Raymond, M. D. Bates, A. Aperia, R. A. Felder, and R. M. Carey. "The renal dopamine receptors." Journal of the American Society of Nephrology 2, no. 8 (February 1992): 1265–78. http://dx.doi.org/10.1681/asn.v281265.

Full text
Abstract:
Dopamine is an endogenous catecholamine that modulates many functions including behavior, movement, nerve conduction, hormone synthesis and release, blood pressure, and ion fluxes. Dopamine receptors in the brain have been classically divided into D1 and D2 subtypes, based on pharmacological data. However, molecular biology techniques have identified many more dopamine receptor subtypes. Several of the receptors cloned from the brain correspond to the classically described D1 and D2 receptors. Several D1 receptor subtypes have been cloned (D1A, D1B, and D5) and are each coupled to the stimulation of adenylyl cyclase. The D2 receptor has two isoforms, a shorter form, composed of 415 amino acids, is termed the D2short receptor. The long form, called the D2long receptor, is composed of 444 amino acids; both are coupled to the inhibition of adenylyl cyclase. The D3 and D4 receptors are closely related to, but clearly distinct from, the D2 receptor. They have not yet been linked to adenylyl cyclase activity. Outside of the central nervous system, the peripheral dopamine receptors have been classified into the DA1 and DA2 subtypes, on the basis of synaptic localization. The pharmacological properties of DA1 receptors roughly approximate those of D1 and D5 receptors, whereas those of DA2 receptors approximate those of D2 receptors. A renal dopamine receptor with some pharmacological features of the D2 receptor but not linked to adenylyl cyclase has been described in the renal cortex and inner medulla. In the inner medulla, this D2-like receptor, termed DA2k, is linked to stimulation of prostaglandin E2 production, apparently due to stimulation of phospholipase A2. Of the cloned dopamine receptors, only the mRNA of the D3 receptor has been reported in the kidney. The DA1 receptor in the kidney is associated with renal vasodilation and an increase in electrolyte excretion. The DA1-related vasodilation and inhibition of electrolyte transport is mediated by cAMP. The role of renal DA2 receptors remains to be clarified. Although DA1 and DA2 receptors may act in concert to decrease transport in the renal proximal convoluted tubule, the overall function of DA2 receptors may be actually the opposite of those noted for DA1 receptors. Dopamine has been postulated to act as an intrarenal natriuretic hormone. Moreover, an aberrant renal dopaminergic system may play a role in the pathogenesis of some forms of hypertension. A decreased renal production of dopamine and/or a defective transduction of the dopamine signal is/are present in some animal models of experimental hypertension as well as in some forms of human essential hypertension.
APA, Harvard, Vancouver, ISO, and other styles
2

Hussain, Tahir, and Mustafa F. Lokhandwala. "Renal Dopamine Receptors and Hypertension." Experimental Biology and Medicine 228, no. 2 (February 2003): 134–42. http://dx.doi.org/10.1177/153537020322800202.

Full text
Abstract:
Dopamine has been recognized as an important modulator of central as well as peripheral physiologic functions in both humans and animals. Dopamine receptors have been identified in a number of organs and tissues, which Include several regions within the central nervous system, sympathetic ganglia and postganglionic nerve terminals, various vascular beds, the heart, the gastrointestinal tract, and the kidney. The peripheral dopamine receptors influence cardiovascular and renal function by decreasing afterload and vascular resistance and promoting sodium excretion. Within the kidney, dopamine receptors are present along the nephron, with highest density on proximal tubule epithelial cells. It has been reported that there is a defective dopamine receptor, especially D1 receptor function, in the proximal tubule of various animal models of hypertension as well as in humans with essential hypertension. Recent reports have revealed the site of and the molecular mechanisms responsible for the defect in D1 receptors in hypertension. Moreover, recent studies have also demonstrated that the disruption of various dopamine receptor subtypes and their function produces hypertension in rodents. In this review, we present evidence that dopamine and dopamine receptors play an important role in regulating renal sodium excretion and that defective renal dopamine production and/or dopamine receptor function may contribute to the development of various forms of hypertension.
APA, Harvard, Vancouver, ISO, and other styles
3

Awenowicz, Patrick W., and Linda L. Porter. "Local Application of Dopamine Inhibits Pyramidal Tract Neuron Activity in the Rodent Motor Cortex." Journal of Neurophysiology 88, no. 6 (December 1, 2002): 3439–51. http://dx.doi.org/10.1152/jn.00078.2002.

Full text
Abstract:
Cortical neurons respond in a variety of ways to locally applied dopamine, perhaps because of the activation of different receptors within or among subpopulations of cells. This study was conducted to assess the effects of dopamine and the receptor subtypes that mediate the responses of a specific population of neurons, the pyramidal tract neurons (PTNs) in the rodent motor cortex. The specific subfamilies of dopamine receptors expressed by PTNs also were determined. PTNs were identified by antidromic stimulation in intact animals. Extracellular recordings of their spontaneous activity and glutamate-induced excitation were performed with multi-barrel pipettes to allow simultaneous recording and iontophoresis of several drugs. Prolonged (30 s) application of dopamine caused a progressive, nonlinear decrease in spontaneous firing rates for nearly all PTNs, with significant reductions from baseline spontaneous activity (71% of baseline levels) occurring between 20 and 30 s of iontophoresis. The D1 selective (SCH23390) and the D2 selective (eticlopride) antagonists were both effective in blocking dopamine-induced inhibition in nearly all PTNs. Mean firing levels were maintained within 3% of baseline levels during co-application of the D1 antagonist with dopamine and within 11% of baseline levels during co-application of the D2 antagonist and dopamine. SCH23390 was ineffective however, in 2 of 16 PTNs, and eticlopride was ineffective in 3 PTNs. The dopamine blockade by both antagonists in most neurons, along with the selective blockade by one, but not the other antagonist in a few neurons indicate that the overall population of PTNs exhibits a heterogeneous expression of dopamine receptors. The firing rate of PTNs was significantly enhanced by iontophoresis of glutamate (mean = 141% of baseline levels). These increases were attenuated significantly (mean= 98% of baseline) by co-application with dopamine in all PTNs, indicating dopaminergic interactions with glutamate transmission. The expression of dopamine receptors was studied with dual-labeling techniques. PTNs were identified by retrograde labeling with fast blue and the D1a, D2, or D5 receptor proteins were stained immunohistochemically. Some, but not all PTNs, showed labeling for D1a, D2, or D5 receptors. The D1a and D2 receptor immunoreactivity was observed primarily in the somata of PTNs, whereas D5 immunoreactivity extended well into the apical dendrites of PTNs. In accordance with findings of D1 and D2 receptor antagonism of dopamine's actions, the identification of three DA receptor subtypes on PTNs suggests that dopamine can directly modulate PTN activity through one or more receptor subtypes.
APA, Harvard, Vancouver, ISO, and other styles
4

Zeng, Chunyu, and Pedro A. Jose. "Dopamine Receptors." Hypertension 57, no. 1 (January 2011): 11–17. http://dx.doi.org/10.1161/hypertensionaha.110.157727.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Felder, R. A., C. C. Felder, G. M. Eisner, and P. A. Jose. "The dopamine receptor in adult and maturing kidney." American Journal of Physiology-Renal Physiology 257, no. 3 (September 1, 1989): F315—F327. http://dx.doi.org/10.1152/ajprenal.1989.257.3.f315.

Full text
Abstract:
Dopamine, like other neurotransmitters, exerts its biological effects by occupation of specific receptor subtypes. The dopamine receptors in the central nervous system and certain endocrine organs are classified into the D1/D2 subtypes. Outside the central nervous system, the dopamine receptors are classified into the DA1/DA2 subtypes. The D1/D2 and DA1/DA2 receptor have marked similarities and some differences, the most notable of which is the lower affinity of the DA dopamine compared with the D dopamine receptor. DA1 receptor activation increases renal blood flow (RBF); stimulation of DA1 and DA2 receptors may also increase glomerular filtration rate (GFR). DA1 agonists inhibit fluid and electrolyte transport indirectly via hemodynamic mechanisms and directly by occupation of DA1 receptors in specific nephron segments. In the proximal tubule, DA1 agonists simulate adenylate cyclase and inhibit Na+-H+ antiport activity. They also increase phospholipase C and inhibit Na+-K+-ATPase activity (presumably as a consequence of protein kinase C activation). The latter effects may be facilitated by DA2 agonists. In cortical collecting ducts, dopamine antagonizes the effects of mineralocorticoids and the hydrosomotic effect of antidiuretic hormone. It has also been suggested that DA1 may also decrease sodium transport by influencing other hormones, such as atrial natriuretic peptide. Studies of dopamine in the young are complicated because of the propensity for dopamine to stimulate alpha-adrenoceptors. Dopamine alone may actually decrease RBF in the perinatal period. In some animals, the renal vasodilatory and natriuretic effects of dopamine increase with age. Renal tubular DA1-stimulated adenylate cyclase activity increases, whereas renal tubular DA1 receptors decrease with age. Renal DA2 receptor density is greater in the fetus; after birth renal DA2 receptors do not change. Endogenous dopamine may regulate sodium excretion in the young differently than in the adult. In the adult, sodium surfeit is associated with an increase in urinary dopamine; the opposite occurs in the young. A decrease in dopamine production or blockade of dopamine receptors results in an antinatriuresis in the adult; dopamine blockade in the young results in a natriuresis. It remains to be determined whether these age-related differences in dopamine effects are due to changes in receptor DA subtype density, second messengers, and/or interaction with other receptors.
APA, Harvard, Vancouver, ISO, and other styles
6

Chazot, P. L., A. J. Doherty, and P. G. Strange. "Antisera specific for D2 dopamine receptors." Biochemical Journal 289, no. 3 (February 1, 1993): 789–94. http://dx.doi.org/10.1042/bj2890789.

Full text
Abstract:
Antisera have been raised against two peptides from the sequence of D2 dopamine receptors: peptide 1 from the predicted second extracellular loop and peptide 2 from the predicted third intracellular loop. The antisera recognize specifically a 95 kDa band in Western blots of several bovine brain regions, which corresponds to the denatured D2 dopamine receptor, whereas in recombinant CHO cells expressing D2 dopamine receptors a 80 kDa band is seen. The antisera immunoprecipitate 10-20% of the D2 dopamine receptors from soluble preparations of bovine brain. The antisera recognize D2 dopamine receptors in immunofluorescence analyses of recombinant CHO cells bearing the receptor gene. The antisera directed against the third intracellular loop, but not those against the second extracellular loop, will interfere with the coupling of D2 dopamine receptors and G-proteins in bovine brain preparations.
APA, Harvard, Vancouver, ISO, and other styles
7

Yamamoto, Kei, Romain Fontaine, Catherine Pasqualini, and Philippe Vernier. "Classification of Dopamine Receptor Genes in Vertebrates: Nine Subtypes in Osteichthyes." Brain, Behavior and Evolution 86, no. 3-4 (2015): 164–75. http://dx.doi.org/10.1159/000441550.

Full text
Abstract:
Dopamine neurotransmission regulates various brain functions, and its regulatory roles are mediated by two families of G protein-coupled receptors: the D1 and D2 receptor families. In mammals, the D1 family comprises two receptor subtypes (D1 and D5), while the D2 family comprises three receptor subtypes (D2, D3 and D4). Phylogenetic analyses of dopamine receptor genes strongly suggest that the common ancestor of Osteichthyes (bony jawed vertebrates) possessed four subtypes in the D1 family and five subtypes in the D2 family. Mammals have secondarily lost almost half of the ancestral dopamine receptor genes, whereas nonmammalian species kept many of them. Although the mammalian situation is an exception among Osteichthyes, the current classification and characterization of dopamine receptors are based on mammalian features, which have led to confusion in the identification of dopamine receptor subtypes in nonmammalian species. Here we begin by reviewing the history of the discovery of dopamine receptors in vertebrates. The recent genome sequencing of coelacanth, gar and elephant shark led to the proposal of a refined scenario of evolution of dopamine receptor genes. We also discuss a current problem of nomenclature of dopamine receptors. Following the official nomenclature of mammalian dopamine receptors from D1 to D5, we propose to name newly identified receptor subtypes from D6 to D9 in order to facilitate the use of an identical name for orthologous genes among different species. To promote a nomenclature change which allows distinguishing the two dopamine receptor families, a nomenclature consortium is needed. This comparative perspective is crucial to correctly interpret data obtained in animal studies on dopamine-related brain disorders, and more fundamentally, to understand the characteristics of dopamine neurotransmission in vertebrates.
APA, Harvard, Vancouver, ISO, and other styles
8

Sunahara, Roger K., Philip Seeman, Hubert H. M. Van Tol, and Hyman B. Niznik. "Dopamine Receptors and Antipsychotic Drug Response." British Journal of Psychiatry 163, S22 (December 1993): 31–38. http://dx.doi.org/10.1192/s000712500029257x.

Full text
Abstract:
Dopamine receptors have been divided into two major types – D1 and D2 – based primarily on pharmacological and biochemical criteria. Recent advances in the molecular biology of the dopamine receptor system have allowed the identification and characterisation of at least five distinct neuronal dopamine receptor genes (D1 to D5). These genes encode dopamine receptors belonging to the D1 receptor family, termed D1 and D5, and three D2-like receptors, termed D2, D3 and D4. These receptors are distinguished on the basis of their primary structure, chromosomal location, mRNA size and tissue distribution, and biochemical and pharmacological differences. Although individually these receptor subtypes may not be directly and exclusively involved in the maintenance or expression of schizophrenia, alterations of any of the receptors may contribute to the perturbation or instability of dopaminergic homeostasis in the brain. What was once thought to be a simple two-receptor system seems to have emerged as an intricate and interactive entity. This review summarises what is currently understood about dopamine receptors, their role in antipsychotic drug action, and their association with psychosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Myslivecek, Jaromir. "Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors." Life 12, no. 5 (April 19, 2022): 606. http://dx.doi.org/10.3390/life12050606.

Full text
Abstract:
The dopaminergic system is one of the most important neurotransmitter systems in the central nervous system (CNS). It acts mainly by activation of the D1-like receptor family at the target cell. Additionally, fine-tuning of the signal is achieved via pre-synaptic modulation by the D2-like receptor family. Some dopamine drugs (both agonists and antagonists) bind in addition to DRs also to α2-ARs and 5-HT receptors. Unfortunately, these compounds are often considered subtype(s) specific. Thus, it is important to consider the presence of these receptor subtypes in specific CNS areas as the function virtually elicited by one receptor type could be an effect of other—or the co-effect of multiple receptors. However, there are enough molecules with adequate specificity. In this review, we want to give an overview of the most common off-targets for established dopamine receptor ligands. To give an overall picture, we included a discussion on subtype selectivity. Molecules used as antipsychotic drugs are reviewed too. Therefore, we will summarize reported affinities and give an outline of molecules sufficiently specific for one or more subtypes (i.e., for subfamily), the presence of DR, α2-ARs, and 5-HT receptors in CNS areas, which could help avoid ambiguous results.
APA, Harvard, Vancouver, ISO, and other styles
10

Liggins, John. "Roles of Dopamine D1 and D2 Receptors in Working Memory Function." McGill Science Undergraduate Research Journal 4, no. 1 (March 31, 2009): 39–45. http://dx.doi.org/10.26443/msurj.v4i1.77.

Full text
Abstract:
Dopamine has been implicated in the modulation of working memory via its interactions with circuits located in the prefrontal cortex of rodents and non-human primates. However, the role that pathways triggered by dopamine receptor subtypes play in affecting processes of working memory remains unclear. In humans, the evidence for dopaminergic modulation of working memory is controversial and the neurological substrates for dopamine’s modulatory effects are not fully understood. This paper will review the major animal and human studies that implicate synaptic dopaminergic transmission in working memory function and will outline a new framework to clarify the specific contribution of dopamine D2 receptors to the performance of this cognitive function. Specifically, it is proposed that activation of hippocampal dopamine D2 receptors by chemical agonists could result in the enhancement of spatial working memory.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Dopamine receptors"

1

Hilditch, A. "Pharmacological characterisation of peripheral dopamine receptors." Thesis, Open University, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.352607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Douglas S. "Dopamine and adenosine receptor function in adult and developing dopamine-deficient mice /." Thesis, Connect to this title online; UW restricted, 2002. http://hdl.handle.net/1773/5063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Obray, J. Daniel. "Peripheral Dopamine 2 Receptors Both Modulate Central Dopamine Release and Adopt in a Similar Manner to that of Central Dopamine 2 Receptors." BYU ScholarsArchive, 2020. https://scholarsarchive.byu.edu/etd/8983.

Full text
Abstract:
Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment and of those who do many will relapse. This highlights a need to develop new treatments for alcohol use disorder that are both more accessible and more effective. This dissertation characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and function following an acute dose of ethanol. This was done by using microdialysis to measure dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the ventral tegmental area to measure dopamine neuron activity and place conditioning to measure the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally, intravenous dopamine produced a modest conditioned place preference. Domperidone, a peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally modulated the sedating effects of ethanol depending on the dose of ethanol administered. The involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells. Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can enhance dopamine levels in the nucleus accumbens and that this effect has relevance in understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful biomarker for central dopamine function.
APA, Harvard, Vancouver, ISO, and other styles
4

Evans, Anthony Mark. "Dopamine receptors of the cockroach salivary gland." Thesis, University of Edinburgh, 1990. http://hdl.handle.net/1842/27986.

Full text
Abstract:
A study has been made of the secretory response and the electrical reponse (a hyperpolarization followed by a depolarization) mediated by dopamine receptors of the cockroach (Nauphoeta cinerea Olivier) salivary gland in-vitro. Although domperidone did not inhibit the electrical response to dopamine, three other actions were observed: one, post-synaptic, led to the potentiation of the hyperpolarization; this action was shared by (±)sulpiride. A separate post-synaptic action resulted in the inhibition of the depolarizing phase of the response. Finally a pre-synaptic action led to the abolition of the response to nerve stimulation.Effects of the calmodulin antagonists W7 and calmidazolium. In an attempt to investigate the role of calmodulin in stimulus-secretion coupling with the salivary gland, the actions of two calmodulin antagonists, W7 and calmidazolium, were studied. In high concentrations, but within the range in which they are known to inhibit calmodulin, W7 and calmidazolium were found to inhibit dopamine-induced secretion and hyperpolarize the acinar cells. The hyperpolarization was not inhibited by SGH23390, and resulted from an increase in cytosolic free calcium, released from the same source as that accessed by dopamine. Lower concentrations of these two antagonists caused submaximal secretion and potentiated dopamine-induced hyperpolarizations. An interpretation of these results is that calmodulin promotes secretion, and exerts a negative control on cytosolic free calcium by an independent process which can be selectively inhibited.
APA, Harvard, Vancouver, ISO, and other styles
5

Hollis, Clare M. "Central and peripheral D←1 dopamine receptors." Thesis, University of Kent, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.292301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Clark, Kenneth Lyle. "Pharmacology of renal dopamine and angiotensin receptors." Thesis, Open University, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.293275.

Full text
Abstract:
Dopamine and angiotensin II (Ang II) are naturally occurring molecules with profound but contrasting effects in the kidney. This study aimed to increase knowledge of the pharmacology and physiology of renal dopamine and angiotensin receptors. Little evidence was found to the presence of dopamine DA1 receptors, mediating dilatation, or angiotensin receptors, mediating constriction, in canine isolated main branch, interlobar, or arcuate renal artery rings. However, in anaesthetised dogs, renal vascular angiotensin and dopamine receptors were clearly demonstrated, suggesting that they are located primarily on renal resistance vessels. In anaesthetised dogs, intra-renal artery (i.r.a.) infusion of the selective dopamine DA1 agonist, fenoldopam, caused local dose-related vasodilatation, and a diuresis which appeared to be due to reduced tubular reabsorption. No evidence was found to suggest that subtypes of renal vascular and tubular dopamine DA1 receptors occur, since the renal vasodilator and diuretic responses to fenoldopam were blocked to a similar extent by the DA1 receptor antagonist, SCH 23390. The inhibitory effect of fenoldopam on renal tubular sodium reabsorption, and its vasodepressor activity were enhanced when angiotensin converting enzyme was inhibited. Thus, these effects may normally be limited by fenoldopam-induced renin release. Attempts to characterise renal tubular dopamine receptors in anaesthetised cats were unfruitful. Renal dopamine DA1 receptors could not be demonstrated in this species, and in contrast to literature reports, the diuretic response to intravenous infusions of dopamine seemed to be mediated by -adrenoceptors. In the renal and mesenteric vascular beds of anaesthetised cats, comparisons were made of the vasoconstrictor potency of Ang II relative to Ang III, and of the antagonist potency (versus Ang II) of the peptide antagonists, lle^7-Ang III and saralasin, and the novel, non-peptide angiotensin AT_1 receptor antagonist, DuP 753. The results suggest that angiotensin receptors in the renal vascular bed share similar broad characteristics to those in the mesenteric. Using lle^7-Ang III, DuP 753, and the non-peptide angiotensin AT_2 receptor ligand, PD 123,177, renal angiotensin receptor pharmacology was further studied in anaesthetised dogs. Tonic effects of endogenous Ang II on renal haemodynamic/tubular function, blood pressure, and aldosterone release appeared to be mediated by angiotensin AT_1 receptors. Similarly, AT_1 receptors appeared to mediate the effects of exogenous Ang II infusions (i.r.a.) on renal haemodynamic and tubular function. However, evidence was found suggesting the presence of subtypes of angiotensin AT_1 receptors on the renal arterioles. Moreover, the AT_2 ligand, PD 123,177 caused some inhibition of renal vasoconstrictor responses to high doses of Ang II, possibly indicating further heterogeneity of renal vascular angiotensin receptors. These findings, and their potential implications, are critically discussed.
APA, Harvard, Vancouver, ISO, and other styles
7

Torvinen, Maria. "Adenosine receptor/dopamine receptor interactions : molecular and biochemical aspects /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-298-1/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tong, Huaxia. "Modulation of NMDA receptor activity by dopamine receptors in the rat striatum." Thesis, University College London (University of London), 2006. http://discovery.ucl.ac.uk/1445880/.

Full text
Abstract:
NMDA receptors are of particular importance in the control of synaptic strength and integration of synaptic activity. Dopamine receptor modulation of NMDA receptors in the striatum may influence the efficacy of synaptic transmission in the cortico-striatal pathway (Calabresi et al., 2000c Centonze et al., 2003) and if so, this modulation will be lost in Parkinson's disease. This change may be an important factor in the changes in the basal ganglia neural network that occur in Parkinson's Disease. In this thesis I have studied dopamine D1 and D2 receptor modulation of NMDA receptors in medium spiny neurons of 7-21 day old rat striatum. The dopamine D1 receptor agonist, SKF-82958, significantly decreased rat striatal NMDA receptor currents in patch-clamp whole-cell recordings from 7 day old rats. This inhibition was not abolished by application of a G protein inhibitor (GDP-p-S) or irreversible activator (GTP-y-S) suggesting a G protein-independent mechanism. In addition, intracellular application of protein tyrosine kinase inhibitors (lavendustin A or PP2) abolished D1 inhibition of NMDA currents. Functional NR2A receptors were absent in 7 day old rat striatum according to my experiments. Single-channel recordings showed that direct D1 receptor inhibition of NMDA receptors can not be observed in isolated membrane patches, which may indicate that D1 inhibition in whole-cell recordings is mediated by a change in NMDA receptor trafficking. Consistent with this hypothesis, intracellular application of a dynamin inhibitory peptide (QVPSRPNRAP) abolished D1 inhibition of NMDA receptor currents. I therefore conclude that a tyrosine kinase-dependent alteration of NMDA receptor trafficking underlies D1 dopamine receptor-mediated down-regulation of NMDA receptor currents in the striatum. The D2 class dopamine receptor agonist, quinpirole, significantly inhibited the NMDAR responses at 1 uM, but at a lower concentration (40 nM) there was no significant effect in 7 day old rat striatum. Replacement of GTP with GDP-P-S in the pipette solution abolished the inhibition induced by 1 uM quinpirole suggesting a G protein-dependent mechanism underlies the D2 family dopamine receptor modulation of NMDA receptors in the striatum.
APA, Harvard, Vancouver, ISO, and other styles
9

Heusner, Carrie L. "Genetic analysis of striatal glutamate-dopamine interactions /." Thesis, Connect to this title online; UW restricted, 2005. http://hdl.handle.net/1773/9212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Oak, James N. "Characterization of epitope-tagged dopamine D¦4 receptors." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0001/MQ45554.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Dopamine receptors"

1

Ian, Creese, and Fraser Claire M, eds. Dopamine receptors. New York: A.R. Liss, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Neve, Kim A., ed. The Dopamine Receptors. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-333-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Neve, Kim A., and Rachael L. Neve, eds. The Dopamine Receptors. Totowa, NJ: Humana Press, 1997. http://dx.doi.org/10.1007/978-1-4757-2635-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

A, Neve Kim, and Neve Rachael L, eds. The dopamine receptors. Totowa, N.J: Humana Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Goldstein, Menek, Kjell Fuxe, and Irving Tabachnick, eds. Central D1 Dopamine Receptors. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4899-2723-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Symposium on Central D₁ Dopamine Receptors (1986 New York, N.Y.). Central D₁ dopamine receptors. New York: Plenum Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tiberi, Mario. Dopamine receptor technologies. New York, NY: Humana Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

L, Waddington John, ed. D1:D2 dopamine receptor interactions. London: Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

R, Breese George, and Creese Ian, eds. Neurobiology of central Dl-dopamine receptors. New York: Plenum Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

R, Breese George, and Creese Ian, eds. Neurology of central D1-dopamine receptors. New York: Plenum, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Dopamine receptors"

1

Nichols, David E. "Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors." In The Dopamine Receptors, 75–99. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Prante, Olaf, Miriam Dörfler, and Peter Gmeiner. "Dopamine Receptor Subtype-Selective Drugs: D2-Like Receptors." In The Dopamine Receptors, 101–35. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Neve, Kim A. "Dopamine Receptors." In Dopamine and Glutamate in Psychiatric Disorders, 3–43. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-852-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fuxe, Kjell, Daniel Marcellino, Diego Guidolin, Amina Woods, and Luigi Agnati. "Dopamine Receptor Oligomerization." In The Dopamine Receptors, 255–80. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Seeman, Philip. "Historical Overview: Introduction to the Dopamine Receptors." In The Dopamine Receptors, 1–21. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cepeda, Carlos, Véronique M. André, Emily L. Jocoy, and Michael S. Levine. "Dopamine Receptor Modulation of Glutamatergic Neurotransmission." In The Dopamine Receptors, 281–302. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tirotta, Emanuele, Claudia De Mei, Chisato Iitaka, Maria Ramos, Dawn Holmes, and Emiliana Borrelli. "Unraveling the Role of Dopamine Receptors In Vivo: Lessons from Knockout Mice." In The Dopamine Receptors, 303–22. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

O’Sullivan, Gerard J., Colm O’Tuathaigh, Katsunori Tomiyama, Noriaki Koshikawa, and John L. Waddington. "Dopamine Receptors and Behavior: From Psychopharmacology to Mutant Models." In The Dopamine Receptors, 323–71. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Seamans, Jeremy K., and Trevor W. Robbins. "Dopamine Modulation of the Prefrontal Cortex and Cognitive Function." In The Dopamine Receptors, 373–98. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Abi-Dargham, Anissa, and Marc Laruelle. "In Vivo Imaging of Dopamine Receptors." In The Dopamine Receptors, 399–430. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Dopamine receptors"

1

Wang, Xiaoxin, Ke Li, Jiali Cheng, Yanhang Zhang, and Lijuan Hou. "Research Progress of Dopamine Receptors and Motor Control." In 2017 2nd International Symposium on Advances in Electrical, Electronics and Computer Engineering (ISAEECE 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/isaeece-17.2017.2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Trzaskowski, Bartosz, and Kinga Ostrowska. "Targeting depression via computational approaches to design new coumarinbased serotonin receptor antagonists/agonists and develop reliable models of G protein-coupled receptors." In 2nd International Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.010t.

Full text
Abstract:
It has been over 60 years since the pharmacological mechanisms of action of antidepressant drugs and the role of serotonin, norepinephrine, and dopamine in depression and other neurological disorders have been established. Since then, a very large number of chemical compounds targeting among others, serotonin and dopamine receptors have been developed. Here we present the most recent approaches to design and develop a new class of coumarinbased candidates for antidepressants with the help of computational studies
APA, Harvard, Vancouver, ISO, and other styles
3

ARDEN, John. "SEARCHING FOR HAPPINESS IN THE WRONG PLACES." In Proceedings of The Third International Scientific Conference “Happiness and Contemporary Society”. SPOLOM, 2022. http://dx.doi.org/10.31108/7.2022.2.

Full text
Abstract:
Addiction mechanisms are described from neuropsychological perspective and explicated in terms of false happiness seeking. The reward pathways in the brain are analyzed. Methods and techniques for sustainable happiness are suggested and argued. Key words: happiness, pleasure, addiction, dopamine receptors, brain networks.
APA, Harvard, Vancouver, ISO, and other styles
4

Mahdavi, Ali, Mina Mirjalili, Fariba Bahrami, and Mahyar Janahmadi. "Hypofunction of NMDA receptors due to the hyperactivation of dopamine receptors in the hippocampal synapses of schizophrenia based mathematical model." In 2015 22nd Iranian Conference on Biomedical Engineering (ICBME). IEEE, 2015. http://dx.doi.org/10.1109/icbme.2015.7404134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kline, Christina Leah B., Amriti Lulla, Jessica Wagner, David Dicker, Marie Baumeister, Sophie Oster, and Wafik El-Deiry. "Abstract 3213: Antagonism of D2-like dopamine receptors plays a role in Onc201’s anticancer effects." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nichiporenko, A. A., G. A. Balakireva, D. V. Podrezova, and E. N. Turalina. "Age aspects of the effect of blocking D2/D3 dopamine receptors with sulpiride on the behavioral parameters." In II Международная конференция, посвящеенная 100- летию И.А. Држевецкой. СКФУ, 2022. http://dx.doi.org/10.38006/9612-62-6.2022.239.243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rashid, Habiba. "Interplay Between Muscarinic And Dopamine Receptors Activity On Retrieving Hippocampal Dependent Memories In Male And Female Mice." In International Conference on Biological Research and Applied Science. Jinnah University for Women, Karachi,Pakistan, 2022. http://dx.doi.org/10.37962/ibras/2022/46-48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Budiono, Budiono, Sumirah Budi Pertami, Siti Nur Arifah, and Sri Rahayu Lestari. "Molecular docking analysis of Polyscias scutellaria active compounds as inhibitor of dopamine D2 receptors to increase prolactin secretion." In INTERNATIONAL CONFERENCE ON LIFE SCIENCES AND TECHNOLOGY (ICoLiST 2020). AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0052655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pavletić, Pegi. "Development of a novel class of brain penetrant ligands endowed with high affinity and selectivity for dopamine D4 receptors." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07926.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sheikhpour, Mojhgan, Ghasem Ahangari, Majid Sadeghizadeh, and Kian khodadad. "Abstract 5316: Significant changes in D2-like dopamine gene receptors expression associated with non- small -cell lung cancer: A case control study." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5316.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Dopamine receptors"

1

Yan, Qingshan. Ethanol and Mesolimbic Serotonin/Dopamine Interactions Via 5-HT1B Receptors. Fort Belvoir, VA: Defense Technical Information Center, March 2006. http://dx.doi.org/10.21236/ada455523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yan, Qingshan. Ethanol and Mesolimbic Serotonin/Dopamine Interactions via 5HT-1B Receptors. Fort Belvoir, VA: Defense Technical Information Center, March 2003. http://dx.doi.org/10.21236/ada416991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yan, Qingshan. Ethanol and Mesolimbic Serotonin/Dopamine Interactions via 5-HT-1B Receptors. Fort Belvoir, VA: Defense Technical Information Center, March 2005. http://dx.doi.org/10.21236/ada443060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dr. Jogeshwar Mukherjee. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Office of Scientific and Technical Information (OSTI), January 2009. http://dx.doi.org/10.2172/944919.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mukherjee, J. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Progress report 1994--1997. Office of Scientific and Technical Information (OSTI), August 1999. http://dx.doi.org/10.2172/764610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Dopamine receptors' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography